Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) FCF Margin (2016 - 2026)

Champions Oncology has reported FCF Margin over the past 17 years, most recently at 9.12% for Q1 2026.

  • Quarterly results put FCF Margin at 9.12% for Q1 2026, down 949.0% from a year ago — trailing twelve months through Jan 2026 was 7.31% (up 1169.0% YoY), and the annual figure for FY2025 was 12.29%, up 2619.0%.
  • FCF Margin for Q1 2026 was 9.12% at Champions Oncology, up from 9.79% in the prior quarter.
  • Over the last five years, FCF Margin for CSBR hit a ceiling of 55.9% in Q2 2025 and a floor of 37.09% in Q3 2023.
  • Median FCF Margin over the past 5 years was 0.36% (2025), compared with a mean of 1.49%.
  • Biggest five-year swings in FCF Margin: tumbled -3019bps in 2023 and later skyrocketed 7484bps in 2025.
  • Champions Oncology's FCF Margin stood at 18.78% in 2022, then tumbled by -77bps to 4.41% in 2023, then tumbled by -148bps to 2.1% in 2024, then crashed by -367bps to 9.79% in 2025, then rose by 7bps to 9.12% in 2026.
  • The last three reported values for FCF Margin were 9.12% (Q1 2026), 9.79% (Q4 2025), and 2.24% (Q3 2025) per Business Quant data.